Hims & Hers Health, Inc. Class A Common Stock (HIMS)

Hims & Hers stock dipped after Novo Nordisk pulled back its partnership for a weight loss drug distribution, though that may not mean much.

A look at the top 20 most-searched tickers on Benzinga Pro for the first six months of 2025.

A look at the top 20 most-searched stock tickers for the month of June on Benzinga Pro.

Amazon's latest data center will reportedly require the same amount of electricity as 1 million homes.

Last week's worst performers include CRCL, HIMS, VG, QXO, CRWV, DUOL, EQIX, EQNR, CF, and EC. Are they in your portfolio?

Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories.

Check out the companies making headlines this week:

The stock's market-beating momentum has come crashing to a halt, following shocking allegations from one of the world's largest pharmaceutical companies.

A highly volatile stock can deliver big gains - or just as easily wipe out a portfolio if things go south. While some investors embrace risk, mistakes can be costly for those who aren’t prepared.

Shares of telehealth company Hims & Hers Health (NYSE:HIMS) jumped 12.1% in the afternoon session after the company's CEO stated that it will continue to offer cheaper, compounded versions of GLP-1 weight-loss drugs. This statement comes on the heels of Novo Nordisk's recent termination of its partnership with Hims & Hers, where it was to supply its branded weight-loss drug, Wegovy. Novo Nordisk ended the collaboration citing concerns over Hims & Hers' promotion and sale of compounded drugs. 

Hims & Hers Health Inc. (NYSE: HIMS) shares are trading higher Thursday. The stock appears to be bouncing back a bit after selling off to start the week. Here's a look at what you need to know.